Successful Experience Utilizing Dexrazoxane Treatment for an Anthracycline ExtravasationMERCER TYSON, Abby; GAY, Wendy E.The Annals of pharmacotherapy. 2010, Vol 44, Num 5, pp 922-925, issn 1060-0280, 4 p.Article

Dexrazoxane: A promising antidote in the treatment of accidental extravasation of anthracyclinesJENSEN, Jesper Nested; LOCK-ANDERSEN, Jørgen; LANGER, Seppo W et al.Scandinavian journal of plastic and reconstructive surgery and hand surgery. 2003, Vol 37, Num 3, pp 174-175, issn 0284-4311, 2 p.Article

Long-term survival in osteosarcoma patients following retinoblastoma using doxorubicin, cisplatin, and methotrexateSTINE, Kimo C; SAYLORS, Robert L; SACCENTE, Suzanne et al.Medical and pediatric oncology. 2003, Vol 41, Num 1, pp 77-78, issn 0098-1532, 2 p.Article

Cardioprotective effect of early dexrazoxane use in anthracycline treated pediatric patientsKANG, Minkyoung; KYUNG IM KIM; SONG, Young-Cheon et al.Journal of chemotherapy (Testo stampato). 2012, Vol 24, Num 5, pp 292-296, issn 1120-009X, 5 p.Article

Treatment of anthracycline extravasation with Savene (dexrazoxane) : results from two prospective clinical multicentre studiesMOURIDSEN, H. T; LANGER, S. W; GIACCONE, G et al.Annals of oncology. 2007, Vol 18, Num 3, pp 546-550, issn 0923-7534, 5 p.Article

Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell deathPOPELOVA, O; STERBA, M; HASKOVA, P et al.British journal of cancer. 2009, Vol 101, Num 5, pp 792-802, issn 0007-0920, 11 p.Article

Dihydroorotase catalyzes the ring opening of the hydrolysis intermediates of the cardioprotective drug dexrazoxane (ICRF-187)SCHROEDER, Patricia E; DAVIDSON, Jeffrey N; HASINOFF, Brian B et al.Drug metabolism and disposition. 2002, Vol 30, Num 12, pp 1431-1435, issn 0090-9556, 5 p.Article

In vitro and in vivo study on the antioxidant activity of dexrazoxaneGALETTA, Fabio; FRANZONI, Ferdinando; CERVETTI, Giulia et al.Biomedicine & pharmacotherapy. 2010, Vol 64, Num 4, pp 259-263, issn 0753-3322, 5 p.Article

Effect of epimbicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patientsGALETTA, Fabio; FRANZONI, Ferdinando; CERVETTI, Giulia et al.Biomedicine & pharmacotherapy. 2005, Vol 59, Num 10, pp 541-544, issn 0753-3322, 4 p.Article

Clinical pharmacology of dexrazoxaneHOCHSTER, H. S.Seminars in oncology. 1998, Vol 25, Num 4, pp 37-42, issn 0093-7754, SUP10Article

Dexrazoxane in combination with anthracyclines lead to a synergistic cytotoxic response in acute myelogenous leukemia cell linesPEARLMAN, Michael; JENDIROBA, David; PAGLIARO, Lance et al.Leukemia research. 2003, Vol 27, Num 7, pp 617-626, issn 0145-2126, 10 p.Article

Dexrazoxane provided moderate protection in a catecholamine model of severe cardiotoxicityZATLOUKALOVA, Libuse; FILIPSKY, Tomas; MLADENKA, Premysl et al.Canadian journal of physiology and pharmacology. 2012, Vol 90, Num 4, pp 473-484, issn 0008-4212, 12 p.Article

Cardioprotective effect of dexrazoxane in a rat model of myocardial infarction: Anti-apoptosis and promoting angiogenesisLIGANG ZHOU; TZ SUNG, Rita Yn; KAREN LI et al.International journal of cardiology. 2011, Vol 152, Num 2, pp 196-201, issn 0167-5273, 6 p.Article

The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel reviewSWAIN, S. M; VICI, P.Journal of cancer research and clinical oncology. 2004, Vol 130, Num 1, pp 1-7, issn 0171-5216, 7 p.Article

Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolismCUSACK, B. J; GAMBLIEL, H; MUSSER, B et al.Cancer chemotherapy and pharmacology. 2006, Vol 58, Num 4, pp 517-526, issn 0344-5704, 10 p.Article

Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignanciesCHOW, Warren A; SYNOLD, Timothy W; MORGAN, Robert J et al.Cancer chemotherapy and pharmacology. 2004, Vol 54, Num 3, pp 241-248, issn 0344-5704, 8 p.Article

Experimental study of dexrazoxane-anthracycline combinations using the model of isolated perfused rat heartPLANDE, Joëlle; PLATEL, Denis; TARIOSSE, Liliane et al.Toxicology letters. 2006, Vol 161, Num 1, pp 37-42, issn 0378-4274, 6 p.Article

Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisoneLANGER, Seppo W; THOUGAARD, Annemette V; SEHESTED, Maxwell et al.Cancer chemotherapy and pharmacology. 2006, Vol 57, Num 1, pp 125-128, issn 0344-5704, 4 p.Article

Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patientsELBL, Lubomir; HRSTKOVA, Hana; TOMASKOVA, Iva et al.European journal of pediatrics. 2005, Vol 164, Num 11, pp 678-684, issn 0340-6199, 7 p.Article

Protective effects of dexrazoxane against acute ischaemia/reperfusion injury of rat heartsNECKAR, Jan; BOUDIKOVA, Adéla; MANDIKOVA, Petra et al.Canadian journal of physiology and pharmacology. 2012, Vol 90, Num 9, pp 1303-1310, issn 0008-4212, 8 p.Conference Paper

Management of anthracycline extravasation injuriesREEVES, David.The Annals of pharmacotherapy. 2007, Vol 41, Num 7-8, pp 1238-1242, issn 1060-0280, 5 p.Article

Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patientsANDERSON, Barry.Pediatric blood & cancer. 2005, Vol 44, Num 7, pp 584-588, issn 1545-5009, 5 p.Conference Paper

Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metal-chelating form in the ratSCHROEDER, Patricia E; HASINOFF, Brian B.Drug metabolism and disposition. 2005, Vol 33, Num 9, pp 1367-1372, issn 0090-9556, 6 p.Article

The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemiaLIPSHULTZ, Steven E; RIFAI, Nader; HURWITZ, Craig A et al.The New England journal of medicine. 2004, Vol 351, Num 2, pp 145-153, issn 0028-4793, 9 p.Article

Dexrazoxane : A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapyWISEMAN, L. R; SPENCER, C. M.Drugs (Basel). 1998, Vol 56, Num 3, pp 385-403, issn 0012-6667Article